← BrightSpring Health Services, Inc. Common Stock overview

BrightSpring Health Services, Inc. Common Stock vs Quest Diagnostics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BrightSpring Health Services, Inc. Common Stock (BTSG)

Q3 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

August 2026
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Latest
▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

  • Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.

    This is the core new operational driver behind the company's raised guidance and stock rally.

  • Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.

    This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.

  • IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.

    This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.

  • Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.

    This is the key fundamental event that set the stage for the period's positive momentum.

Quest Diagnostics Incorporated (DGX)

Q3 2026
▲4

Quest raises 2026 outlook on strong Q2 and new test approval

  • New York approval opens Haystack MRD to all 50 states New York State approved Quest's Haystack MRD liquid biopsy test, making it available in all 50 states. This regulatory win expands the market for a high-value cancer test, supporting future revenue growth and lifting DGX shares.

    This is a new regulatory milestone that directly expands Quest's addressable market for a premium test.

  • Attunio Health picks Quest as national lab backbone Attunio Health selected Quest as its national lab partner for precision psychiatry, with at-home blood collection via Getlabs. This adds new test volume from a growing mental health platform, a modest but positive demand driver for DGX.

    A new partnership that adds incremental testing volume and shows Quest winning new business.

  • Q2 beat and raised 2026 guidance boost outlook Quest reported Q2 revenue up 10.2% to $3.04B and adjusted EPS of $3.12, beating estimates, and raised full-year 2026 revenue and EPS guidance. Strong organic growth and a tax benefit drove the increase, signaling momentum.

    The guidance raise and earnings beat are the core fundamental drivers of the stock's recent move.

  • Analysts raise fair value and price targets after Q2 Analysts lifted Quest's fair value estimate to $239.38 from $223.44, with price targets mostly $245–$265. The upgrades reflect the earnings beat and higher guidance, though UBS stayed Neutral on margin concerns, a mild counterweight.

    Analyst upgrades following the earnings beat reinforce the positive sentiment and help explain the stock's rise.

July 2026
▲4

Quest raises 2026 outlook on strong Q2 and new test approval

  • New York approval opens Haystack MRD to all 50 states New York State approved Quest's Haystack MRD liquid biopsy test, making it available in all 50 states. This regulatory win expands the market for a high-value cancer test, supporting future revenue growth and lifting DGX shares.

    This is a new regulatory milestone that directly expands Quest's addressable market for a premium test.

  • Attunio Health picks Quest as national lab backbone Attunio Health selected Quest as its national lab partner for precision psychiatry, with at-home blood collection via Getlabs. This adds new test volume from a growing mental health platform, a modest but positive demand driver for DGX.

    A new partnership that adds incremental testing volume and shows Quest winning new business.

  • Q2 beat and raised 2026 guidance boost outlook Quest reported Q2 revenue up 10.2% to $3.04B and adjusted EPS of $3.12, beating estimates, and raised full-year 2026 revenue and EPS guidance. Strong organic growth and a tax benefit drove the increase, signaling momentum.

    The guidance raise and earnings beat are the core fundamental drivers of the stock's recent move.

  • Analysts raise fair value and price targets after Q2 Analysts lifted Quest's fair value estimate to $239.38 from $223.44, with price targets mostly $245–$265. The upgrades reflect the earnings beat and higher guidance, though UBS stayed Neutral on margin concerns, a mild counterweight.

    Analyst upgrades following the earnings beat reinforce the positive sentiment and help explain the stock's rise.

Latest
▲4

Quest raises 2026 outlook on strong Q2 and new test approval

  • New York approval opens Haystack MRD to all 50 states New York State approved Quest's Haystack MRD liquid biopsy test, making it available in all 50 states. This regulatory win expands the market for a high-value cancer test, supporting future revenue growth and lifting DGX shares.

    This is a new regulatory milestone that directly expands Quest's addressable market for a premium test.

  • Attunio Health picks Quest as national lab backbone Attunio Health selected Quest as its national lab partner for precision psychiatry, with at-home blood collection via Getlabs. This adds new test volume from a growing mental health platform, a modest but positive demand driver for DGX.

    A new partnership that adds incremental testing volume and shows Quest winning new business.

  • Q2 beat and raised 2026 guidance boost outlook Quest reported Q2 revenue up 10.2% to $3.04B and adjusted EPS of $3.12, beating estimates, and raised full-year 2026 revenue and EPS guidance. Strong organic growth and a tax benefit drove the increase, signaling momentum.

    The guidance raise and earnings beat are the core fundamental drivers of the stock's recent move.

  • Analysts raise fair value and price targets after Q2 Analysts lifted Quest's fair value estimate to $239.38 from $223.44, with price targets mostly $245–$265. The upgrades reflect the earnings beat and higher guidance, though UBS stayed Neutral on margin concerns, a mild counterweight.

    Analyst upgrades following the earnings beat reinforce the positive sentiment and help explain the stock's rise.

© 2026 MarketIVWhy